NEJM Group (@nejmgroup) 's Twitter Profile
NEJM Group

@nejmgroup

Information about NEJM Group products and services. Follow @NEJM, @NEJMCatalyst, @NEJMEvidence, @NEJM_AI, @NEJMres360, @NEJMkplus, and @JWatch.

ID: 437804849

linkhttp://www.nejmgroup.org/ calendar_today15-12-2011 21:17:06

2,2K Tweet

9,9K Followers

179 Following

PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

The FDA has issued emergency use authorizations for two new #COVID19 treatments, including the antibody cocktail President Donald Trump received early in his illness.

NEJM Catalyst (@nejmcatalyst) 's Twitter Profile Photo

In response to its outstanding reception, NEJM Catalyst Innovations in Care Delivery is doubling its frequency to 12 issues per year. Learn about the journal and visit our author center: catalyst.nejm.org/about/journal #HealthCareDelivery #HCLDR #HealthCareInnovation

NEJM Journal Watch (@jwatch) 's Twitter Profile Photo

From the Insights on Residency Training blog: Vivek Sant, MD, who has seen residents collectively judge each new class of interns since his own intern year, muses about the culture shift he sees happening in residency training today. jwat.ch/3fySo46

From the Insights on Residency Training blog: <a href="/VivekSantMD/">Vivek Sant, MD</a>, who has seen residents collectively judge each new class of interns since his own intern year, muses about the culture shift he sees happening in residency training today. jwat.ch/3fySo46
PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

The CDC's advisory committee voted 13-1 on Tuesday in favor of prioritizing both healthcare workers and residents of long-term-care facilities for vaccination against #SARSCoV2 during the initial phase of vaccination. #vaccine #COVID19

NEJM Catalyst (@nejmcatalyst) 's Twitter Profile Photo

What is your organization doing to advance the transformation of health care? Visit our author center and let us know: catalyst.nejm.org/author-center #HealthCareDelivery #HCLDR #HealthCareInnovation

PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

The CDC has shortened the minimum amount of time people have to quarantine after a potential #COVID19 exposure from 14 days to as few as 7 days as long as the person is symptom free and tests negative.

PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

Inhaled corticosteroids can be used as needed to manage symptoms in patients aged 12 years and up with mild or moderate persistent #asthma, according to updated asthma guidelines from the National Asthma Education and Prevention Program.

NEJM Journal Watch (@jwatch) 's Twitter Profile Photo

#ASH2020 news from NEJM Group: Dr. Terry Gernsheimer discusses her team's research on the prophylactic use of tranexamic acid in patients undergoing treatment for hematologic malignancies jwat.ch/2LdbCRB

#ASH2020 news from <a href="/NEJMGroup/">NEJM Group</a>: Dr. Terry Gernsheimer discusses her team's research on the prophylactic use of tranexamic acid in patients undergoing treatment for hematologic malignancies jwat.ch/2LdbCRB
PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

#ASH20 news from NEJM Group: Joe Elia interviews Dr. Bhavana Bhatnagar. She reports that African-American patients aged <60 with acute myeloid leukemia have lower 3-year survival compared with whites: 32% vs. 41%. jwat.ch/39P1BUL Bhavana Bhatnagar

#ASH20 news from <a href="/NEJMGroup/">NEJM Group</a>: Joe Elia interviews Dr. Bhavana Bhatnagar. She reports that African-American patients aged &lt;60 with acute myeloid leukemia have lower 3-year survival compared with whites: 32% vs. 41%. jwat.ch/39P1BUL <a href="/BhavanaBhatnag4/">Bhavana Bhatnagar</a>
NEJM Journal Watch (@jwatch) 's Twitter Profile Photo

.Paul Sax offers some tips for getting through the next few months safely -- and with some joy -- while we await widespread vaccination against #COVID19. jwat.ch/2VHpAgu

PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

A preliminary study in California shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions don't fare any better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with Joe Elia. jwat.ch/39R6Jb2 #ASH20

A preliminary study in California shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions don't fare any better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with Joe Elia. jwat.ch/39R6Jb2 #ASH20
PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

Pfizer and BioNTech's mRNA #vaccine against #SARSCoV2 seems to start working soon after the first dose. Meanwhile, the AstraZeneca vaccine showed 62% efficacy among people who received two full doses and 90% efficacy among those who received a half-dose followed by a full dose.

NEJM Journal Watch (@jwatch) 's Twitter Profile Photo

#ASH2020: A preliminary study shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions do not fare better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with NEJM Group’s Joe Elia. jwat.ch/39R6Jb2

#ASH2020: A preliminary study shows that patients on chronic anticoagulant or antiplatelet drugs for other conditions do not fare better than other patients after receiving a diagnosis of #COVID19. Dr. Gwendolyn Ho chats with <a href="/NEJMGroup/">NEJM Group</a>’s Joe Elia. jwat.ch/39R6Jb2
NEJM Catalyst (@nejmcatalyst) 's Twitter Profile Photo

Celebrating our anniversary today! 🎉 One year ago, we launched NEJM Catalyst Innovations in Care Delivery. NEJM Catalyst itself turns five. Please enjoy some virtual cake, on us. 🍰

PhysiciansFirstWatch (@physns1stwatch) 's Twitter Profile Photo

An FDA advisory committee voted on Thursday that the potential benefits of the Pfizer and BioNTech #COVID19 #vaccine outweigh its risks for people ages 16 years and up.

NEJM Group (@nejmgroup) 's Twitter Profile Photo

This Twitter account is no longer active. For up-to-date information and articles from NEJM Group, follow NEJM, @NEJMCatalyst, NEJM Journal Watch, PhysiciansFirstWatch, @NEJMres360, @nejmkplus, and NEJM LibraryHub.